Discover Veru Inc.'s Q3 2025 earnings insights, including Phase III enobosarm trial updates, FDA feedback, and nondilutive funding plans for ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its ...

A large-scale cohort study has found that GLP-1s, including Ozempic and Wegovy, may be associated with a modestly increased risk of developing diabetic retinopathy. The research, published Aug. 11 in ...

Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

The Today’s Dietitian 13th annual Spring Symposium will be returning to vibrant Orlando, Florida, in 2026. Secure your spot today by registering at www.todaysdietitian.com/ss26. We are excited to see ...

A company that has Donald Trump Jr. on its board debuted a new service to help pharmaceutical companies launch direct sales ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

Data suggests that some sectors of Europe's confectionery sector are declining. Could GLP-1s have a role to play in this?

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

Peptide therapeutics are rapidly emerging as a promising class of interventions for obesity, driven by growing insights into their ability to modulate key ...

After work or on weekends, groups of friends gather at long, wooden tables at the four New York City locations of Clinton ...